The role of ixekizumab in the treatment of nonradiographic axial spondyloarthritis

References

• Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet 390(10089), 73–84 (2017).
   PubMed Web of Science ®Google Scholar
• Ceribelli A, Motta F, Vecellio M, Isailovic N, Ciccia F, Selmi C. Clinical trials supporting the role of the IL-17/IL-23 axis in axial spondyloarthritis. Front. Immunol. 12, 622770 (2021).
   PubMed Web of Science ®Google Scholar
• Rudwaleit M, Khan MA, Sieper J. The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria? Arthritis Rheum. 52(4), 1000–1008 (2005).
   PubMed Web of Science ®Google Scholar
• Sieper J, Van Der Heijde D. Nonradiographic axial spondyloarthritis: new definition of an old disease? Arthritis Rheum. 65(3), 543–551 (2013).
   PubMed Web of Science ®Google Scholar
• Deodhar A, Strand V, Kay J, Braun J. The term ‘nonradiographic axial spondyloarthritis’ is much more important to classify than to diagnose patients with axial spondyloarthritis. Ann. Rheum. Dis. 75(5), 791–794 (2016).
   PubMed Web of Science ®Google Scholar
• Rudwaleit M, Van Der Heijde D, Landewé R et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann. Rheum. Dis. 68(6), 777–783 (2009).
   PubMed Web of Science ®Google Scholar
• Boonen A, Sieper J, Van Der Heijde D et al. The burden of nonradiographic axial spondyloarthritis. Semin. Arthritis Rheum. 44(5), 556–562 (2015).
   PubMed Web of Science ®Google Scholar
• Protopopov M, Poddubnyy D. Radiographic progression in nonradiographic axial spondyloarthritis. Expert Rev. Clin. Immunol. 14(6), 525–533 (2018).
   PubMed Web of Science ®Google Scholar
• Ortolan A, Kiltz U, Doria A, Aggarwal A, Ramonda R. Do we believe in nonradiographic axial spondyloarthritis? A debate. Autoimmun. Rev. 20(1), 102703 (2021).
   PubMed Web of Science ®Google Scholar
• Inman RD. Axial spondyloarthritis: current advances, future challenges. J. Rheum. Dis. 28(2), 55–59 (2021).
   PubMedGoogle Scholar
• Dougados M, Van Der Heijde D, Sieper J et al. Effects of long-term etanercept treatment on clinical outcomes and objective signs of inflammation in early nonradiographic axial spondyloarthritis: 104-week results from a randomized, placebo-controlled study. Arthritis Care Res. 69(10), 1590–1598 (2017).
   Web of Science ®Google Scholar
• Deodhar A, Van Der Heijde D, Gensler LS et al. Ixekizumab for patients with nonradiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial. Lancet 395(10217), 53–64 (2020).
   PubMed Web of Science ®Google Scholar
• Deodhar A, Blanco R, Dokoupilová E et al. Improvement of signs and symptoms of nonradiographic axial spondyloarthritis in patients treated with secukinumab: primary results of a randomized, placebo-controlled Phase III study. Arthritis Rheum. 73(1), 110–120 (2021).
   PubMed Web of Science ®Google Scholar
• Fossiez F, Djossou O, Chomarat P et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J. Exp. Med. 183(6), 2593–2603 (1996).
   PubMed Web of Science ®Google Scholar
• Amatya N, Garg AV, Gaffen SL. IL-17 signaling: the yin and the yang. Trends Immunol. 38(5), 310–322 (2017).
   PubMed Web of Science ®Google Scholar
• Lubberts E. The IL-23–IL-17 axis in inflammatory arthritis. Nat. Rev. Rheumatol. 11(7), 415–429 (2015).
   PubMed Web of Science ®Google Scholar
• Parham C, Chirica M, Timans J et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rβ1 and a novel cytokine receptor subunit, IL-23R. J. Immunol. 168(11), 5699–5708 (2002).
   PubMed Web of Science ®Google Scholar
• Le Goff B, Bouvard B, Lequerre T et al. Implication of IL-17 in bone loss and structural damage in inflammatory rheumatic diseases. Mediators Inflamm. 2019, (2019).
   Web of Science ®Google Scholar
• Garraud K, Cleret A, Mathieu J et al. Differential role of the interleukin-17 axis and neutrophils in resolution of inhalational anthrax. Infect. Immun. 80(1), 131–142 (2012).
   PubMed Web of Science ®Google Scholar
• Ye P, Rodriguez FH, Kanaly S et al. Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J. Exp. Med. 194(4), 519–528 (2001).
   PubMed Web of Science ®Google Scholar
• Koshy P, Henderson N, Logan C, Life P, Cawston T, Rowan A. Interleukin 17 induces cartilage collagen breakdown: novel synergistic effects in combination with proinflammatory cytokines. Ann. Rheum. Dis. 61(8), 704–713 (2002).
   PubMed Web of Science ®Google Scholar
• Ha H-L, Wang H, Pisitkun P et al. IL-17 drives psoriatic inflammation via distinct, target cell-specific mechanisms. Proc. Nat. Acad. Sci. USA 111(33), E3422–E3431 (2014).
   PubMed Web of Science ®Google Scholar
• Zhang J-R, Pang D-D, Tong Q, Liu X, Su D-F, Dai S-M. Different modulatory effects of IL-17, IL-22, and IL-23 on osteoblast differentiation. Mediators Inflamm. 2017, (2017).
   Web of Science ®Google Scholar
• Song L, Tan J, Wang Z et al. Interleukin-17A facilitates osteoclast differentiation and bone resorption via activation of autophagy in mouse bone marrow macrophages. Mol Med Rep. 19(6), 4743–4752 (2019).
   PubMed Web of Science ®Google Scholar
• Chabaud M, Page G, Miossec P. Enhancing effect of IL-1, IL-17, and TNF-α on macrophage inflammatory protein-3α production in rheumatoid arthritis: regulation by soluble receptors and Th2 cytokines. J. Immunol. 167(10), 6015–6020 (2001).
   PubMed Web of Science ®Google Scholar
• Mcgonagle DG, Mcinnes IB, Kirkham BW, Sherlock J, Moots R. The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies. Ann. Rheum. Dis. 78(9), 1167–1178 (2019).
   PubMed Web of Science ®Google Scholar
• Jo S, Wang SE, Lee YL et al. IL-17A induces osteoblast differentiation by activating JAK2/STAT3 in ankylosing spondylitis. Arthritis Res Ther. 20(1), 1–10 (2018).
   PubMedGoogle Scholar
• Ono T, Okamoto K, Nakashima T et al. IL-17-producing γδ T cells enhance bone regeneration. Nat. Commun. 7(1), 1–9 (2016).
   Google Scholar
• Croes M, Øner FC, Van Neerven D et al. Proinflammatory T cells and IL-17 stimulate osteoblast differentiation. Bone 84, 262–270 (2016).
   PubMed Web of Science ®Google Scholar
• Sato K, Suematsu A, Okamoto K et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J. Exp. Med. 203(12), 2673–2682 (2006).
   PubMed Web of Science ®Google Scholar
• Kotake S, Udagawa N, Takahashi N et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J. Clin. Invest. 103(9), 1345–1352 (1999).
   PubMed Web of Science ®Google Scholar
• Taams LS, Steel KJ, Srenathan U, Burns LA, Kirkham BW. IL-17 in the immunopathogenesis of spondyloarthritis. Nat. Rev. Rheumatol. 14(8), 453–466 (2018).
   PubMed Web of Science ®Google Scholar
• Brown MA, Pile KD, Kennedy LG et al. HLA class I associations of ankylosing spondylitis in the white population in the United Kingdom. Ann. Rheum. Dis. 55(4), 268–270 (1996).
   PubMed Web of Science ®Google Scholar
• Burton P, Clayton D, Cardon L, Consortium WTCC. Australo-Anglo-American Spondylitis Consortium (TASC). Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat. Genet. 39(11), 1329–1337 (2007).
   PubMed Web of Science ®Google Scholar
• Evans DM, Spencer CC, Pointon JJ et al. Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. Nat. Genet. 43(8), 761–767 (2011).
   PubMed Web of Science ®Google Scholar
• Cortes A, Hadler J, Pointon J et al. International Genetics of Ankylosing Spondylitis Consortium (IGAS); Australo-Anglo-American Spondyloarthritis Consortium (TASC); Groupe Française d'Etude Génétique des Spondylarthrites (GFEGS); Nord-Trøndelag Health Study (HUNT); Spondyloarthritis Research Consortium of Canada (SPARCC); Wellcome Trust Case Control Consortium 2 (WTCCC2)(2013). Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. Nat. Genet. 45, 730–738 (2013).
   PubMed Web of Science ®Google Scholar
• Filer C, Ho P, Smith RL et al. Investigation of association of the IL12B and IL23R genes with psoriatic arthritis. Arthritis Rheum. 58(12), 3705–3709 (2008).
   PubMedGoogle Scholar
• Jostins L, Ripke S, Weersma RK et al. Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491(7422), 119–124 (2012).
   PubMed Web of Science ®Google Scholar
• Coffre M, Roumier M, Rybczynska M et al. Combinatorial control of Th17 and Th1 cell functions by genetic variations in genes associated with the interleukin-23 signaling pathway in spondyloarthritis. Arthritis Rheum. 65(6), 1510–1521 (2013).
   PubMed Web of Science ®Google Scholar
• Mei Y, Pan F, Gao J et al. Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis. Clin. Rheumatol. 30(2), 269–273 (2011).
   PubMed Web of Science ®Google Scholar
• Chen W-S, Chang Y-S, Lin K-C et al. Association of serum interleukin-17 and interleukin-23 levels with disease activity in Chinese patients with ankylosing spondylitis. J Chin/ Med. Assoc. 75(7), 303–308 (2012).
   PubMed Web of Science ®Google Scholar
• Xueyi L, Lina C, Zhenbiao W, Qing H, Qiang L, Zhu P. Levels of circulating Th17 cells and regulatory T cells in ankylosing spondylitis patients with an inadequate response to anti- TNF-α therapy. J. Clin. Immunol. 33(1), 151–161 (2013).
   PubMed Web of Science ®Google Scholar
• Appel H, Maier R, Wu P et al. Analysis of IL-17+ cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response. Arthritis Res Ther. 13(3), 1–9 (2011).
   Web of Science ®Google Scholar
• Torgutalp M, Poddubnyy D. IL-17 inhibition in axial spondyloarthritis: current and future perspectives. Expert Opin. Biol. Ther. 19(7), 631–641 (2019).
   PubMed Web of Science ®Google Scholar
• Tse MT. IL-17 antibodies gain momentum. Nat. Rev. Drug Discov 12(11), 815 (2013).
   PubMed Web of Science ®Google Scholar
• Baeten D, Sieper J, Braun J et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N. Engl. J. Med. 373(26), 2534–2548 (2015).
   PubMed Web of Science ®Google Scholar
• Pavelka K, Kivitz A, Dokoupilova E et al. Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind Phase III study, MEASURE 3. Arthritis Res Ther. 19(1), 1–10 (2017).
   PubMedGoogle Scholar
• Kivitz AJ, Wagner U, Dokoupilova E et al. Efficacy and safety of secukinumab 150 mg with and without loading regimen in ankylosing spondylitis: 104-week results from MEASURE 4 study. Rheumatol Ther. 5(2), 447–462 (2018).
   PubMed Web of Science ®Google Scholar
• Baraliakos X, Braun J, Deodhar A et al. Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the Phase III MEASURE 1 extension study. RMD Open 5(2), e001005 (2019).
   PubMed Web of Science ®Google Scholar
• Marzo-Ortega H, Sieper J, Kivitz AJ et al. 5-year efficacy and safety of secukinumab in patients with ankylosing spondylitis: end-of-study results from the Phase III MEASURE 2 trial. Lancet Rheumatol. 2(6), e339–e346 (2020).
   PubMedGoogle Scholar
• Huang F, Sun F, Wan W-G et al. Secukinumab provided significant and sustained improvement in the signs and symptoms of ankylosing spondylitis: results from the 52-week, Phase III China-centric study, MEASURE 5. Chin. Med. J. 133(21), 2521–2531 (2020).
   PubMed Web of Science ®Google Scholar
• Ramonda R, Lorenzin M, Sole Chimenti M et al. Effectiveness and safety of secukinumab in axial spondyloarthritis: a 24-month prospective, multicenter real-life study. Ther Adv Musculoskelet. Dis. 14, 1759720X221090310 (2022).
   PubMed Web of Science ®Google Scholar
• Blair HA. Secukinumab: a review in ankylosing spondylitis. Drugs 79(4), 433–443 (2019).
   PubMed Web of Science ®Google Scholar
• Liu L, Lu J, Allan BW et al. Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A. J. Inflamm. Res. 9, 39 (2016).
   PubMed Web of Science ®Google Scholar
• Paul C. Ixekizumab or secukinumab in psoriasis: what difference does it make? Br. J. Dermatol. 178(5), 1003–1005 (2018).
   PubMed Web of Science ®Google Scholar
• Genovese MC, Mysler E, Tomita T et al. Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials. Rheumatology (Oxford). 59(12), 3834–3844 (2020).
   PubMed Web of Science ®Google Scholar
• Deodhar A, Poddubnyy D, Pacheco-Tena C et al. Efficacy and safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: sixteen-week results from a Phase III randomized, double-blind, placebo-controlled trial in patients with prior inadequate response to or intolerance of tumor necrosis factor inhibitors. Arthritis Rheum. 71(4), 599–611 (2019).
   PubMed Web of Science ®Google Scholar
• Van Der Heijde D, Wei JC-C, Dougados M et al. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a Phase III randomised, double-blind, active-controlled and placebo-controlled trial. Lancet 392(10163), 2441–2451 (2018).
   PubMed Web of Science ®Google Scholar
• Glatt S, Baeten D, Baker T et al. Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. Ann. Rheum. Dis. 77(4), 523–532 (2018).
   PubMed Web of Science ®Google Scholar
• Glatt S, Helmer E, Haier B et al. First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis. Br. J. Clin. Pharmacol. 83(5), 991–1001 (2017).
   PubMed Web of Science ®Google Scholar
• Papp KA, Merola JF, Gottlieb AB et al. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial. J. Am. Acad. Dermatol. 79(2), 277–286. e210 (2018).
   PubMed Web of Science ®Google Scholar
• Van Der Heijde D, Gensler LS, Deodhar A et al. Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study. Ann. Rheum. Dis. 79(5), 595–604 (2020).
   PubMed Web of Science ®Google Scholar
• Nirula A, Nilsen J, Klekotka P et al. Effect of IL-17 receptor A blockade with brodalumab in inflammatory diseases. Rheumatology (Oxford). 55(Suppl. 2), ii43–ii55 (2016).
   PubMedGoogle Scholar
• Mease PJ, Helliwell PS, Hjuler KF, Raymond K, Mcinnes I. Brodalumab in psoriatic arthritis: results from the randomised Phase III AMVISION-1 and AMVISION-2 trials. Ann. Rheum. Dis. 80(2), 185–193 (2021).
   PubMed Web of Science ®Google Scholar
• Wei JC-C, Kim T-H, Kishimoto M, Ogusu N, Jeong H, Kobayashi S. Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, Phase III trial. Ann. Rheum. Dis. 80(8), 1014–1021 (2021).
   PubMed Web of Science ®Google Scholar
• Nakagawa H, Niiro H, Ootaki K, Group JBS. Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: efficacy and safety results from a phase II randomized controlled study. J. Dermatol. Sci. 81(1), 44–52 (2016).
   PubMed Web of Science ®Google Scholar
• Papp K, Reich K, Paul C et al. A prospective Phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br. J. Dermatol. 175(2), 273–286 (2016).
   PubMed Web of Science ®Google Scholar
• Mazurov V, Erdes SF, Gaydukova I et al. Long-term efficacy and safety of netakimab in the treatment of ankylosing spondylitis: results of Phase III international, multicenter, randomized double-blind clinical trial BCD-085-5/ASTERA. Mod Rheumatol. 14(4), 39–49 (2020).
   Google Scholar
• Ramiro S, Nikiphorou E, Sepriano A et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann. Rheum. Dis. 82(1), 19–34 (2023).
   PubMed Web of Science ®Google Scholar
• Webers C, Ortolan A, Sepriano A et al. Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis. Ann. Rheum. Dis. 82(1), 130–141 (2023).
   PubMed Web of Science ®Google Scholar
• Sieper J, Van Der Heijde D, Dougados M et al. Efficacy and safety of adalimumab in patients with nonradiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann. Rheum. Dis. 72(6), 815–822 (2013).
   PubMed Web of Science ®Google Scholar
• Sieper J, Van Der Heijde D, Dougados M et al. A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis. Arthritis Rheum. 67(10), 2702–2712 (2015).
   PubMed Web of Science ®Google Scholar
• Arends S, Brouwer E, Van Der Veer E et al. Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study. Arthritis Res Ther. 13(3), 1–10 (2011).
   Web of Science ®Google Scholar
• Glintborg B, Ústergaard M, Krogh NS, Dreyer L, Kristensen HL, Hetland ML. Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry. Ann. Rheum. Dis. 69(11), 2002–2008 (2010).
   PubMed Web of Science ®Google Scholar
• Rudwaleit M, Schwarzlose S, Hilgert E, Listing J, Braun J, Sieper J. MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis. Ann. Rheum. Dis. 67(9), 1276–1281 (2008).
   PubMed Web of Science ®Google Scholar
• Dougados M, Van Der Heijde D, Sieper J et al. Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 66(8), 2091–2102 (2014).
   PubMed Web of Science ®Google Scholar
• Ciurea A, Kissling S, Bürki K et al. Current differentiation between radiographic and nonradiographic axial spondyloarthritis is of limited benefit for prediction of important clinical outcomes: data from a large, prospective, observational cohort. RMD Open. 8(1), e002067 (2022).
   PubMed Web of Science ®Google Scholar
• Landewé R, Braun J, Deodhar A et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase III study. Ann. Rheum. Dis. 73(1), 39–47 (2014).
   PubMed Web of Science ®Google Scholar
• Lie E, Lindström U, Zverkova-Sandström T et al. Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register. Ann. Rheum. Dis. 76(9), 1515–1521 (2017).
   PubMed Web of Science ®Google Scholar
• Lindström U, Bengtsson K, Olofsson T et al. Anterior uveitis in patients with spondyloarthritis treated with secukinumab or tumour necrosis factor inhibitors in routine care: does the choice of biological therapy matter? Ann. Rheum. Dis. 80(11), 1445–1452 (2021).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Hanauer SB, Katz S et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 121(5), 1088–1094 (2001).
   PubMed Web of Science ®Google Scholar
• Hueber W, Sands BE, Lewitzky S et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 61(12), 1693–1700 (2012).
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359(9317), 1541–1549 (2002).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Hanauer SB, Rutgeerts P et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 56(9), 1232–1239 (2007).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Stoinov S et al. Certolizumab pegol for the treatment of Crohn's disease. N. Engl. J. Med. 357(3), 228–238 (2007).
   PubMed Web of Science ®Google Scholar
• Adedokun OJ, Xu Z, Marano CW et al. Pharmacokinetics and exposure-response relationship of golimumab in patients with moderately-to-severely active ulcerative colitis: results from phase 2/3 PURSUIT induction and maintenance studies. J. Crohns Colitis 11(1), 35–46 (2017).
   PubMed Web of Science ®Google Scholar
• Targan SR, Feagan B, Vermeire S et al. A randomized, double-blind, placebo-controlled phase 2 study of brodalumab in patients with moderate-to-severe Crohn's disease. Am. J. Gastroenterol. 111(11), 1599–1607 (2016).
   PubMed Web of Science ®Google Scholar
• De Morales JMGR, Puig L, Daudén E et al. Critical role of interleukin (IL)-17 in inflammatory and immune disorders: an updated review of the evidence focusing in controversies. Autoimmun. Rev. 19(1), 102429 (2020).
   PubMed Web of Science ®Google Scholar
• Mcinnes IB, Behrens F, Mease PJ et al. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, Phase IIIb trial. Lancet 395(10235), 1496–1505 (2020).
   PubMed Web of Science ®Google Scholar
• Mease PJ, Smolen JS, Behrens F et al. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Ann. Rheum. Dis. 79(1), 123–131 (2020).
   PubMed Web of Science ®Google Scholar
• Sieper J, Rudwaleit M, Baraliakos X et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann. Rheum. Dis. 68(Suppl. 2), ii1–ii44 (2009).
   PubMed Web of Science ®Google Scholar
• Walsh JA, Magrey MN, Baraliakos X et al. Improvement of functioning and health with ixekizumab in the treatment of active nonradiographic axial spondyloarthritis in a 52-week, randomized, controlled trial. Arthritis Care Res. 74(3), 451–460 (2022).
   Web of Science ®Google Scholar
• Braun J, Kiltz U, Deodhar A et al. Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST. RMD Open 8(2), e002165 (2022).
   PubMed Web of Science ®Google Scholar
• Mease P, Roussou E, Burmester GR et al. Safety of ixekizumab in patients with psoriatic arthritis: results from a pooled analysis of three clinical trials. Arthritis Care Res. 71(3), 367–378 (2019).
   PubMed Web of Science ®Google Scholar
• Strober B, Leonardi C, Papp KA et al. Short-and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: etanercept comparisons and integrated data. J. Am. Acad. Dermatol. 76(3), 432–440. e417 (2017).
   PubMed Web of Science ®Google Scholar
• Baraliakos X, Borah B, Braun J et al. Long-term effects of secukinumab on MRI findings in relation to clinical efficacy in subjects with active ankylosing spondylitis: an observational study. Ann. Rheum. Dis. 75(2), 408–412 (2016).
   PubMed Web of Science ®Google Scholar
• Braun J, Baraliakos X, Deodhar A et al. Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised Phase III MEASURE 1 study. Ann. Rheum. Dis. 76(6), 1070–1077 (2017).
   PubMed Web of Science ®Google Scholar
• Fowler E, Ghamrawi R, Ghiam N, Liao W, Wu J. Risk of tuberculosis reactivation during interleukin-17 inhibitor therapy for psoriasis: a systematic review. J. Eur. Acad. Dermatol. Venereol. 34(7), 1449–1456 (2020).
   PubMed Web of Science ®Google Scholar
• San Koo B, Kim T-H. The role of ixekizumab in nonradiographic axial spondyloarthritis. Ther. Adv. Musculoskelet. Dis. 13, 1759720X20986734 (2021).
   PubMed Web of Science ®Google Scholar